Emily Fukuchi, MD; Barbara Fetterman, SCT (ASCP); Nancy Poitras, ACS, PMP; Walter Kinney, MD; Thomas Lorey, MD; Ramey D. Littell, MD To evaluate whether the presence of CIN 1 on ECC contributes to ...
Phase II trial of paclitaxel plus doxorubicin plus carboplatin in patients with intermediate risk, high risk, or recurrent endometrial carcinoma No significant financial relationships to disclose.
When a woman has an abnormal pap smear she usually undergoes colposcopy. Typically a metal instrument is used to obtain a small sampling of cells inside the cervix -- an oftentimes painful procedure ...
Femasys Inc., a medical device developer of women's healthcare solutions, announced today the U.S. launch of the 510(k) cleared FemCerv™, an innovative endocervical curettage device. FemCerv is ...
ATLANTA, May 03, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally ...
The adjusted incidence of cervical carcinoma among Israeli Jewish women is ∼5 out of 100 000. This retrospective study sought to determine the clinical implications of finding atypical glandular cells ...
The aim of this study was to evaluate the usefulness of p16 staining in predicting the outcome of biopsy proven LSIL/CIN1 lesions, in a large prospective series of patients recruited at a single ...
Objective. This study aimed to characterize the 24-month risk of cervical intraepithelial neoplasia grade 2 or worse (CIN 2+) and grade 3 or worse (CIN 3+) in women with low-risk cytological finding ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback